Maximized Value in ADME-Tox Research through continuous development of services

Posted on March 1, 2024

Drug discovery is an ever-evolving process; at Admescope, we are committed to continuous improvement of our services and portfolio, and we want to update you on how our latest internal Research and Development (R&D) initiatives are providing significant value. We also presented the highlights of our research activities in various recent scientific meetings e.g. at ISSX/DMDG during 2023.

Oligonucleotide Therapies

In 2023, we expanded our ADME-Tox/DMPK services to cover oligonucleotides. For this type of compound class, special considerations are required for experimental design – from more laborious sample prep to managing the likelihood of high non-specific binding and optimized analytical steps with a purpose-fit dedicated instrumentation.

Admescope’s experienced scientific team has been instrumental in delivering several oligonucleotide metabolism studies since 2023 when we expanded the scope of our ADME-Tox/DMPK services into this therapeutic class. Please don’t hesitate to reach out if you’d like to find out more information about our various oligonucleotide offerings.

HTS screening

In drug discovery and development projects, speed and turnaround time are of the utmost importance. As we recognize the importance of efficiency and precision, our R&D efforts emphasize increased automation.

Starting from laboratory processes, we leverage cutting-edge technologies to streamline workflows, reduce turnaround times, and enhance operational efficiency. This commitment to automation translates into tangible benefits for your organization, ensuring timely and accurate results to optimize the design-make-test cycle.

For the needs of early-stage projects, we have optimal set ups including shake-flask logD/elogD, stability, RED PPB and solubility assays for cost-effective screening of a high number of compounds in a timely manner and those can be complemented with other in vitro or in vivo screening assays.

Low Clearance Compounds Expertise

Addressing the challenges of low clearance compounds requires specialized knowledge and innovative approaches in drug metabolism. Admescope was founded on the cornerstone of in vitro drug metabolism and our capabilities have expanded well beyond the typical approaches.

As an example, co-culture models can be applied to low clearance compounds to investigate metabolic stability over several days or elucidating the CYP enzyme responsible for the metabolism.

In vivo DMPK Excellence

Despite the advances in applying various in vitro models for predicting the fate of the compound, in vivo studies are essential. Our AAALAC-accredited in vivo facility was expanded last year, and with increased capacity, our in vivo PK team is dedicated to advancing methodologies that provide comprehensive insights into the in vivo behavior of compounds, covering various modalities.

Our capabilities include initial PK screening approaches with one-week turnaround time for discovery process, to comprehensive experimental set ups including collection of excreta and mass balance studies with radiolabeled compound for development stage.

Looking Ahead:

Throughout 2024, we look forward to updating you on more of our cutting-edge R&D projects, and we welcome the opportunity to talk to you about any unique ADME-Tox issues you face. As the biotech and pharma industries evolve, so does Admescope and we are ready to partner with you for your pre-clinical studies for small molecules, low clearance compounds, oligonucleotides, ADCs, PROTACs, peptides and more.

Should you have any questions or if you’d like to explore how these advancements can specifically benefit your organization, please do not hesitate to reach out. We look forward to continuing our shared journey of innovation and success.

Stay tuned, you can expect exciting news soon!

Feel free to contact us!

Curious to know more about what can we do for you? Get in touch and let’s start a conversation.

Contact us